Title: Buy Erlonat/Erlotinib 150mg tablets with price | Myapplepharma
1Erlonat 150mg tablet Erlotinib 150mg tablets
2Erlonat 150mg tablet (Erlotinib)
- Erlonat tablets consist of active ingredients
known as Erlotinib (Generic Tarceva), that is
considered as quinazoline derivative and
anti-cancer agents that responses as a protein
kinase prohibitors for EGFR related to tyrosine
kinase. - Erlonat is majorly used in the treatment of
non-small cell lung cancer and pancreatic
carcinoma and also involved to treat various
cancers. - Erlonat 150mg is especially aimed the epidermal
growth factor receptor tyrosine kinase.
3USES OF Erlonat
- Erlonat is indicated as continuance therapy, in
patients with long lasting or metastasis non
small cell lung carcinoma, whose disease has not
get advance after four cycles with platinum based
first line therapy - Erlonat is used in this condition only after the
failure of one prior chemotherapy regimen. - Erlonat 150mg with platinum based compounds like
Carboplatin, gemcitabine or cisplatin.
4Erlonat WORKS
- Erlonat has pharmacological effects like
anti-neoplastic activity, which exhibits its
action by inhibiting the intracellular
phosphorylation of tyrosine kinase related with
epidermal growth factor receptor. - This EGFR is present on the surface of the tumor
cells. - Thus results as inhibition causes interfere with
signal transduction and lead to cell lyses.
5PHARMACOKINETICS
- The peak plasma concentration time reaches at 4
hours after drug intake After an oral
administration of Erlonat, causes 60 of oral
bioavailability. Increased by meals to 100. - Smoking should be avoided during the treatment
with Erlonat 150mg, causes decreasing the
exposure of Erlotinib. The apparent volume of
distribution of Erlotinib is 232L Human protein
binding to Erlotinib is occurs as 93. - Erlotinib metabolites occurs via Feces 83
urine 8 half life period of Erlotinib is 36.2
hours.
6WARNING AND PRECAUTIONS
- Pulmonary toxicity Interstitial lung disease and
other pulmonary toxicity conditions, Avoid the
treatment with Erlonat Renal failure Frequent
monitoring of renal function or serum
electrolytes occurs or avoids the treatment - Hepatic function should be periodically
monitored, or otherwise discontinue the therapy
with Erlonat.
7SOME INTERACTION WITH SOME OTHER DRUGS
- Co administration of Erlonat with midazolam
causes decreasing the AUC of CYP3A4 substrate.
Drugs involved in alteration of pH levels causes
variation in solubility of Erlotinib. Avoid
concomitant use of gastric regulators
with Erlonat. - Erlonat concomitant with statins drugs (lipid
lowering drug), causes increasing the
concentration of these drugs (rosuvastatin,
simvastatin or atorvastatin). - CYP3A4 strong inhibitors like itraconazole, grape
fruit juice, rotonavir, indinavir etc CYP3A4
inducers concurrently used with Erlonat tablets
causes decreasing the exposure of Erlotinib.
8CONTRAINDICATION
- In Erlonat 150mg therapy, no contraindication
occurs. - In some patients hypersensitivity reactions
present due to patients are contraindicated to
the ingredients in Erlonat. - In case of missed dose, patients must consult
with medical oncologist and follow the regular
dosing schedule.
9SIDE EFFECTS
- some undesirable effects like
- Paronychia, Bullous, blistering and expoliative
skin conditions like Stevens Johnsons syndrome.
Gastrointestinal perforation Hepatic failure
occurs during monotherapy or combination with
other chemotherapy agents - Some common side effects
- Diarrhea, Fatigue, Anorexia, Pruritus, Acne,
Dermatitis, Dry skin, Loss of weight, Paronychia,
Cough, Vomiting, Conjunctivitis,
Keratoconjuctivities sicca, Abdominal pain,
Stomatits, Infection, nausea, Bone pain,
Alopecia, Anxiety, Neuropathy, Renal disorders,
hepatic disorders, ocular disorders, skin, hair
and nail disorders.
10Contact Us
- phone No 9987711567
- Email info_at_myapplepharma.com
- website
- https//myapplepharma.com/erlonat-150mg.php